Merck has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies.
Allergan and Editas Medicine on Tuesday announced that the companies entered into a strategic R&D alliance under which Allergan will receive exclusive access...
Allergan and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine's genome-editing ocular programs, including its lead pr
Gene editing in human embryos has been given the go-ahead by a panel of experts from the US National Academy of Sciences (NAS) and the National Academy of Medicine following an international committee in Washington, DC, but only in very specific circumsta